Clinical trial reportCancer immunology, immunotherapy : CIIPublished
A phase 1 study of VAC85135, a neoantigen vaccine regimen targeting calreticulin and JAK2 mutations, in combination with ipilimumab in patients with myeloproliferative neoplasms
Regional connection
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
- Institution
- Johnson & Johnson
- Counties
- Mercer County, Montgomery County
Publication record
- Type
- Clinical trial report
- Venue
- Cancer immunology, immunotherapy : CII
- Published
- Topic
- Clinical care
- Subject terms
- Humans; Myeloproliferative Disorders; Calreticulin; Cancer Vaccines; Antigens, Neoplasm; Mutation; Adult; Aged; Aged, 80 and over; Middle Aged; Female; Male
- PubMed ID
- 43052517
- PubMed Central ID
- PMC13782046
- Open access
- Yes, open
- Added to directory
- Source checked